Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Net Cash Flow (2016 - 2025)

Rein Therapeutics filings provide 10 years of Net Cash Flow readings, the most recent being -$815000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 83.06% year-over-year to -$815000.0, compared with a TTM value of -$9.6 million through Dec 2025, down 114.76%, and an annual FY2025 reading of -$9.6 million, down 114.76% over the prior year.
  • Net Cash Flow hit -$815000.0 in Q4 2025 for Rein Therapeutics, up from -$1.6 million in the prior quarter.
  • The five-year high for Net Cash Flow was $11.7 million in Q1 2021, with the low at -$8.5 million in Q2 2021.
  • Median Net Cash Flow over the past 5 years was -$1.4 million (2023), compared with a mean of -$215850.0.
  • The sharpest move saw Net Cash Flow crashed 397.89% in 2021, then soared 2907.82% in 2023.
  • Year by year, Net Cash Flow stood at -$4.0 million in 2021, then surged by 108.87% to $355000.0 in 2022, then soared by 1394.93% to $5.3 million in 2023, then crashed by 190.65% to -$4.8 million in 2024, then soared by 83.06% to -$815000.0 in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$815000.0, -$1.6 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.